Macquarie University ( Site 0151)(1.3 mi away)Contact
+212 other location
castration-resistant prostate cancer
adenocarcinoma of prostate
metastatic castration-resistant prostate cancer
The purpose of this study is to assess the efficacy and safety of the combination of the
polyadenosine 5'-diphosphoribose poly(ADP-ribose) polymerase (PARP) inhibitor olaparib and
pembrolizumab in the treatment of participants with mCRPC who have failed to respond to
either abiraterone acetate or enzalutamide (but not both) and to chemotherapy.
The primary study hypotheses are that the combination of pembrolizumab plus olaparib is
superior to abiraterone acetate or enzalutamide with respect to:
Overall Survival (OS) and
Radiographic progression-free survival (rPFS) per Prostate Cancer Working Group
(PCWG)-modified Response Evaluation Criteria in Solid Tumors Version 1.1 as assessed by
blinded independent central review (BICR)
If you are confirmed eligible after full screening, you will be required to understand and sign the informed consent if you decide to enroll in the study. Once enrolled you may be asked to make scheduled visits over a period of time.
Every year hundreds of thousands of volunteers step forward to participate in research. Sign up as a volunteer and receive email notifications when clinical trials are posted in the medical category of interest to you.